In the latest Phase 3 trial, participants taking Orforglipron lost up to 14.7% of their body weight after 36 weeks
Cost accounts for some of that - but studies looking at the drivers of early discontinuation consistently identify side effect intolerance and lack of behavioral support as factors independent of cost
10.1056/NEJMoa1614362 19 GhidewonM.WaldH
Appetite suppression is maintained by the medication ongoing pharmacological effects, not by permanent metabolic changes
GLP-1RA Use Patterns and Discontinuation Rates The study included 201,136 incident sulfonylurea users and 132,551 incident GLP-1RA users, with a median follow-up of three years
#DiabetesCare #MedicationAdherence #DiabetesManagement #BloodSugarControl #PatientEducation #DefeatDiabetese To view or add a comment, sign in Your ears feel blocked, but there's no infection